226 related articles for article (PubMed ID: 27984486)
1. A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series.
Yu R; Nissen NN; Hendifar A; Tang L; Song YL; Chen YJ; Fan X
Pancreas; 2017 Jan; 46(1):48-56. PubMed ID: 27984486
[TBL] [Abstract][Full Text] [Related]
2. A malignant cause of hypoglycaemia: a metastatic insulin-secreting pancreatic neuroendocrine carcinoma.
Sandoval MA; Pagsisihan D; Berberabe A; Palugod-Lopez EG
BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26994053
[TBL] [Abstract][Full Text] [Related]
3. Tumor and serum levels of proinsulin and insulin in insulinoma patients.
Tasaka Y; Nakaya F; Matsumoto H; Odagiri R; Ohgawara H; Omori Y
Endocr J; 1993 Apr; 40(2):245-8. PubMed ID: 7951510
[TBL] [Abstract][Full Text] [Related]
4. ANTHROPOMETRIC FEATURES ARE NOT PREDICTIVE OF 72-HOUR FAST DURATION IN INSULINOMAS.
Donegan D; Jakubikova I; Vella A
Endocr Pract; 2017 Aug; 23(8):923-928. PubMed ID: 28614004
[TBL] [Abstract][Full Text] [Related]
5. Sustained pulsatile insulin secretion from adenomatous human beta-cells. Synchronous cycling of insulin, C-peptide, and proinsulin.
Chou HF; Ipp E; Bowsher RR; Berman N; Ezrin C; Griffiths S
Diabetes; 1991 Nov; 40(11):1453-8. PubMed ID: 1936605
[TBL] [Abstract][Full Text] [Related]
6. Coincidence of insulinoma with nesidioblastosis or false diagnosis in 2 of 15 patients?
Goretzki PE; Starkel A
Am J Surg Pathol; 2006 Jul; 30(7):919-20; author reply 920-1. PubMed ID: 16819338
[No Abstract] [Full Text] [Related]
7. Natural history of a proinsulin-secreting insulinoma: from symptomatic hypoglycemia to clinical diabetes.
Arioglu E; Gottlieb NA; Koch CA; Doppman JL; Grey NJ; Gorden P
J Clin Endocrinol Metab; 2000 Oct; 85(10):3628-30. PubMed ID: 11061513
[No Abstract] [Full Text] [Related]
8. Transformation of nonfunctioning pancreatic tumor into malignant insulinoma after 3 years: an uncommon clinical course of insulinoma.
Arslan MS; Ozbek M; Karakose M; Tutal E; Ucan B; Yilmazer D; Dilli A; Gultekin SS; Cakal E; Delibasi T
Arch Endocrinol Metab; 2015 Jun; 59(3):270-2. PubMed ID: 26154097
[TBL] [Abstract][Full Text] [Related]
9. [Endogenous hyperinsulinism: two diagnostic challenges].
Gonçalves AP; Baptista F; Nobre E; Carmo Id
Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):71-5. PubMed ID: 24728168
[TBL] [Abstract][Full Text] [Related]
10. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia.
Tessonnier L; Sebag F; Ghander C; De Micco C; Reynaud R; Palazzo FF; Conte-Devolx B; Henry JF; Mundler O; Taïeb D
J Clin Endocrinol Metab; 2010 Jan; 95(1):303-7. PubMed ID: 19915018
[TBL] [Abstract][Full Text] [Related]
11. [Pancreatic proinsulinoma].
Kriger AG; Berelavichus SV; Gorin DS; Panteleev VI; Demidova VS; Davydenko PI; Varava AB; Kaldarov AR
Khirurgiia (Mosk); 2021; (3):5-10. PubMed ID: 33710820
[TBL] [Abstract][Full Text] [Related]
12. Recurrent hyperinsulinemic hypoglycemia caused by an insulin-secreting insulinoma.
Service FJ
Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):467-70; quiz following 470. PubMed ID: 16932336
[TBL] [Abstract][Full Text] [Related]
13. Intracellular degradation of the C-peptide of proinsulin, in a human insulinoma: identification of sites of cleavage and evidence for a role for cathepsin B.
Conlon JM; Höög A; Grimelius L
Pancreas; 1995 Mar; 10(2):167-72. PubMed ID: 7716141
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycemia in response to glucose and glucagon in insulinoma patients with a negative prolonged fast: functional and morphological properties.
Wiesli P; Schmid C; Perren A; Pfammatter T; Spinas GA; Keller U
J Endocrinol Invest; 2004 Oct; 27(9):832-8. PubMed ID: 15648547
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation in insulinoma predicts histopathological tumour characteristics.
Wolf P; Winhofer Y; Smajis S; Anderwald CH; Scheuba C; Niederle B; Gessl A; Luger A; Krebs M; Koperek O
Clin Endocrinol (Oxf); 2015 Jul; 83(1):67-71. PubMed ID: 25817061
[TBL] [Abstract][Full Text] [Related]
16. Comparison of benign and malignant insulinoma.
Sada A; Yamashita TS; Glasgow AE; Habermann EB; Thompson GB; Lyden ML; Dy BM; Halfdanarson TR; Vella A; McKenzie TJ
Am J Surg; 2021 Feb; 221(2):437-447. PubMed ID: 32873371
[TBL] [Abstract][Full Text] [Related]
17. Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors.
Câmara-de-Souza AB; Toyoshima MTK; Giannella ML; Freire DS; Camacho CP; Lourenço DM; Rocha MS; Bacchella T; Jureidini R; Machado MCC; Almeida MQ; Pereira MAA
Pancreatology; 2018 Apr; 18(3):298-303. PubMed ID: 29452754
[TBL] [Abstract][Full Text] [Related]
18. Topographic abnormalities of proinsulin to insulin conversion in functioning human insulinomas. Comparison of immunoelectron microscopic and clinical data.
Roth J; Komminoth P; Heitz PU
Am J Pathol; 1995 Aug; 147(2):489-502. PubMed ID: 7639339
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors.
Murtha TD; Lupsa BC; Majumdar S; Jain D; Salem RR
J Gastrointest Surg; 2017 Aug; 21(8):1335-1341. PubMed ID: 28510792
[TBL] [Abstract][Full Text] [Related]
20. [Autonomy of hormone secretion in insulinoma].
Beischer W; Kerner W; Raptis S; Herfarth C; Pfeiffer EF
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1410-3. PubMed ID: 206049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
